- Home
- CKPT vs TERN Comparison
CKPT vs TERN Comparison
Compare CKPT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- TERN
- Stock Information
- Founded
- CKPT 2014
- TERN 2017
- Country
- CKPT United States
- TERN United States
- Employees
- CKPT N/A
- TERN N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- CKPT Health Care
- TERN Health Care
- Exchange
- CKPT Nasdaq
- TERN Nasdaq
- Market Cap
- CKPT 335.9M
- TERN 298.1M
- IPO Year
- CKPT 2017
- TERN 2021
- Fundamental
- Price
- CKPT $4.04
- TERN $2.40
- Analyst Decision
- CKPT Buy
- TERN Buy
- Analyst Count
- CKPT 3
- TERN 5
- Target Price
- CKPT $4.33
- TERN $18.38
- AVG Volume (30 Days)
- CKPT 1.7M
- TERN 1.3M
- Earning Date
- CKPT 05-09-2025
- TERN 05-12-2025
- Dividend Yield
- CKPT N/A
- TERN N/A
- EPS Growth
- CKPT N/A
- TERN N/A
- EPS
- CKPT N/A
- TERN N/A
- Revenue
- CKPT $41,000.00
- TERN N/A
- Revenue This Year
- CKPT $102,182.93
- TERN N/A
- Revenue Next Year
- CKPT $351.71
- TERN N/A
- P/E Ratio
- CKPT N/A
- TERN N/A
- Revenue Growth
- CKPT N/A
- TERN N/A
- 52 Week Low
- CKPT $1.38
- TERN $1.87
- 52 Week High
- CKPT $4.50
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- CKPT 63.60
- TERN 40.98
- Support Level
- CKPT $3.94
- TERN $2.22
- Resistance Level
- CKPT $4.06
- TERN $2.43
- Average True Range (ATR)
- CKPT 0.05
- TERN 0.24
- MACD
- CKPT -0.03
- TERN 0.04
- Stochastic Oscillator
- CKPT 83.33
- TERN 52.71
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.